From April 2023 Medicare has increased access to continuous glucose monitoring (CGM) in the US to people on insulin therapies who are also having hypoglycemia.
The new rules mean that anybody who takes insulin, no matter their type of diabetes and no matter how many injections, qualifies for CGM. Also eligible are people who aren’t on insulin but are having episodes of hypoglycemia, specifically anybody who has had an episode of severe hypoglycemia or who has had two or more episodes of level 2 hypoglycemia (a glucose level of 3 mmols/L).
Currently, the Medicare-approved CGM devices include the Libre 2 (Abbott Laboratories) and the Dexcom G6 or G7.
To read more, CLICK HERE.
